These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 21902295)
1. Pirfenidone: in idiopathic pulmonary fibrosis. Carter NJ Drugs; 2011 Sep; 71(13):1721-32. PubMed ID: 21902295 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan. Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T; Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105 [TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257 [TBL] [Abstract][Full Text] [Related]
4. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Poletti V; Ravaglia C; Tomassetti S Expert Rev Respir Med; 2014 Oct; 8(5):539-45. PubMed ID: 25113033 [TBL] [Abstract][Full Text] [Related]
5. Pirfenidone: a review of its use in idiopathic pulmonary fibrosis. Kim ES; Keating GM Drugs; 2015 Feb; 75(2):219-30. PubMed ID: 25604027 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study. Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616 [TBL] [Abstract][Full Text] [Related]
7. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM; Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362 [TBL] [Abstract][Full Text] [Related]
8. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Noble PW; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; Lancaster L; Lederer DJ; Leff JA; Nathan SD; Pereira CA; Swigris JJ; Valeyre D; King TE Eur Respir J; 2016 Jan; 47(1):243-53. PubMed ID: 26647432 [TBL] [Abstract][Full Text] [Related]
9. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107 [TBL] [Abstract][Full Text] [Related]
10. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Nathan SD; Albera C; Bradford WZ; Costabel U; Glaspole I; Glassberg MK; Kardatzke DR; Daigl M; Kirchgaessler KU; Lancaster LH; Lederer DJ; Pereira CA; Swigris JJ; Valeyre D; Noble PW Lancet Respir Med; 2017 Jan; 5(1):33-41. PubMed ID: 27876247 [TBL] [Abstract][Full Text] [Related]
12. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. Cottin V Eur Respir Rev; 2012 Jun; 21(124):161-7. PubMed ID: 22654089 [TBL] [Abstract][Full Text] [Related]
13. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626 [TBL] [Abstract][Full Text] [Related]
15. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design. Behr J; Nathan SD; Harari S; Wuyts W; Kirchgaessler KU; Bengus M; Gilberg F; Wells AU Respir Med; 2018 May; 138():13-20. PubMed ID: 29724385 [TBL] [Abstract][Full Text] [Related]
16. The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Cottin V Respir Res; 2013; 14 Suppl 1(Suppl 1):S5. PubMed ID: 23734908 [TBL] [Abstract][Full Text] [Related]
17. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments. Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346 [TBL] [Abstract][Full Text] [Related]
18. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U Respiration; 2017; 93(6):415-423. PubMed ID: 28399537 [TBL] [Abstract][Full Text] [Related]